HIV-1 infection

Active Ingredient: Nevirapine

Indication for Nevirapine

Population group: only children (1 year - 12 years old)

Nevirapine is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected children of any age.

For this indication, competent medicine agencies globally authorize below treatments:

150-300 mg/m² in 1-2 divided doses daily

Route of admnistration

Oral

Defined daily dose

150 - 300 mg per m² of body surface area (BSA)

Dosage regimen

From 75 To 150 mg per m² of body surface area (BSA) 2 time(s) per day every day

Loading dose

150 mg per m² of body surface area (BSA)

Maintenance dose

300 mg per m² of body surface area (BSA)

Detailed description

The total daily dose should not exceed 400 mg for any patient. Nevirapine may be dosed in paediatric patients either by body surface area (BSA) or by body weight as follows:

By BSA using the Mosteller formula the recommended oral dose for paediatric patients of all ages is 150 mg/m² once daily for two weeks followed by 150 mg/m² twice daily thereafter.

4-8 mg/kg in 1-2 divided doses daily

Route of admnistration

Oral

Defined daily dose

4 - 8 mg per kg of body weight

Dosage regimen

From 2 To 4 mg per kg of body weight 2 time(s) per day every day

Loading dose

4 mg per kg of body weight

Maintenance dose

8 mg per kg of body weight

Detailed description

The total daily dose should not exceed 400 mg for any patient. Nevirapine may be dosed in paediatric patients either by body surface area (BSA) or by body weight as follows:

By weight the recommended oral dose for paediatric patients up to 8 years of age is 4 mg/kg once daily for two weeks followed by 7 mg/kg twice daily thereafter. For patients 8 years and older the recommended dose is 4 mg/kg once daily for two weeks followed by 4 mg/kg twice daily thereafter.

Active ingredient

Nevirapine

Nevirapine is a NNRTI of HIV-1. Nevirapine is a non-competitive inhibitor of the HIV-1 reverse transcriptase, but it does not have a biologically significant inhibitory effect on the HIV-2 reverse transcriptase or on eukaryotic DNA polymerases α, β, γ, or δ.

Read more about Nevirapine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.